Nkarta, Inc. (NKTX)
| Market Cap | 161.16M +8.6% |
| Revenue (ttm) | n/a |
| Net Income | -117.32M |
| EPS | -1.58 |
| Shares Out | 71.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 904,869 |
| Open | 2.230 |
| Previous Close | 2.220 |
| Day's Range | 2.140 - 2.307 |
| 52-Week Range | 1.700 - 3.720 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 10.83 (+381.33%) |
| Est. Earnings | Nov 9, 2026 |
About NKTX
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The com... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for NKTX stock is "Strong Buy." The 12-month stock price target is $10.83, which is an increase of 381.33% from the latest price.
News
Nkarta Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
A novel off-the-shelf CD19 CAR NK cell therapy for autoimmune diseases is advancing through streamlined outpatient trials, with strong safety and promising efficacy data to be presented at ACR 2026. Regulatory support enables rapid enrollment and plans for pivotal trials by 2027.
Nkarta Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The conference highlighted progress in off-the-shelf CAR-NK cell therapy for autoimmune diseases, with phase I-II trials ongoing and first data expected at ACR. Scleroderma and myositis are prioritized for phase III, with a focus on efficacy, safety, and patient-reported outcomes.
Nkarta to Participate in September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to trea...
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat au...
Nkarta price target lowered to $10 from $11 at Stifel
Stifel analyst Stephen Willey lowered the firm’s price target on Nkarta (NKTX) to $10 from $11 and keeps a Buy rating on the shares after having updated the firm’s model…
Nkarta price target lowered to $14 from $16 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar lowered the firm’s price target on Nkarta (NKTX) to $14 from $16 and keeps a Buy rating on the shares. The firm cites the company’s…
Nkarta reports Q2 EPS (54c), consensus (36c)
“Expanding access to NKX019 in the communities where autoimmune patients already receive care is central to how we’re advancing this program,” said Paul J. Hastings, Chief Executive Officer of Nkarta…
Nkarta Earnings release: Q2 2026
Nkarta released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Nkarta Quarterly report: Q2 2026
Nkarta has published its Q2 2026 quarterly earnings report on August 10, 2026.
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Paris, France and New York, USA, July 23, 2026 – Cyllene Therapeutics (“Cyllene Tx”), the global leader in non-replicating HSV-1 (nr...
Nkarta Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
A novel CD19-directed CAR-NK cell therapy is advancing through multiple autoimmune disease trials, with a focus on safety, outpatient accessibility, and durable remissions. Key data updates in 2026 will inform future development, with redosing flexibility and regulatory engagement planned.
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside at the H.C. Wainwright Cell Therapy Virtual Conference.
Nkarta initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Nkarta (NKTX) with a Buy rating and no price target Nkarta is focused on the development of engineered natural killer cell therapies, the analyst tells…
Nkarta Transcript: AGM 2026
The meeting covered director elections, ratification of the accounting firm, and executive compensation votes, with all proposals approved by stockholders. No additional proposals or questions were submitted, and a quorum was established with over 75% voting power represented.
Nkarta price target lowered to $9 from $25 at Evercore ISI
Evercore ISI lowered the firm’s price target on Nkarta (NKTX) to $9 from $25 and keeps an Outperform rating on the shares.
Nkarta reports Q1 EPS (37c), consensus (37c)
“Putting patients first and providing access to care in a familiar setting close to home matters” said Paul Hastings, CEO of Nkarta (NKTX). “In early April, we reached agreement with…
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings...
Nkarta Earnings release: Q1 2026
Nkarta released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Nkarta Quarterly report: Q1 2026
Nkarta has published its Q1 2026 quarterly earnings report on May 12, 2026.
Nkarta Slides: Corporate presentation
Nkarta has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Nkarta Proxy statement: Proxy filing
Nkarta filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Nkarta Proxy statement: Proxy filing
Nkarta filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Nkarta announces agreement with FDA on changes to Ntrust-1, Ntrust-2 trials
Nkarta (NKTX) announced that it has reached agreement with the FDA on key changes to the ongoing Ntrust-1 and Ntrust-2 clinical trials. The protocol amendments are designed to alleviate the…
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat au...
Nkarta Transcript: 25th Annual Needham Virtual Healthcare Conference
The conference highlighted a strategic pivot to autoimmune diseases using off-the-shelf CAR-NK cell therapy, with a favorable safety profile and expanding outpatient access. Multiple indications are under study, with a data update and narrowed focus expected later this year. Cash runway extends into 2029.